Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Germany Votes: But What Will Change For Health Care, Medtech Post-Election?

Executive Summary

The German Bundestagswahl – the 2017 general election – looks likely to deliver a fourth straight victory for CDU chief Angela Merkel, Europe's most powerful politician and arguably the world's most powerful national female leader. But she will have to invite coalition partners, as in her previous three regimes, which could spell changes for health and the other ministerial portfolios that touch on medtech.

You may also be interested in...

German Vote 2017: Business Must Wait As Limboland Merkel Faces Hard Coalition Choices

Germany's CDU leader Angela Merkel secured her fourth term as chancellor, but chastened by an election result that saw many of her 2013 voters turn to the liberals and far right, her hand is weakened. Indeed, the EU's rock of political stability has sprung many a surprise in delivering a 2017 election result that will give businesses a sense both of unease and promise, with the re-emergence of the liberal and business-focused FDP.

German Medtechs Aim To Score Useful Points In 2017 Election Year

The 2017 German national election, set for September 24, is not only a chance for Angela Merkel to secure a fourth term in office as Chancellor, but also an opportunity for the medtech industry to tell lawmakers how they can make the health-care system better. The medtech industry has made ten demands of the new government, with recent opinion polls favoring the status quo.

Industry Sees Much To Improve In Germany's New High-Risk Medtech Assessment Scheme

Only two of eight treatments passed muster under Germany's new NUBs scheme for assessing the benefit of high-risk products for inpatient use. As with the country's outpatient assessment counterpart, industry is pushing for changes.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts